




RealRate

PHARMACEUTICAL 2018

International Stem Cell CORP
Rank 258 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

PHARMACEUTICAL 2018

International Stem Cell CORP Rank 258 of 349



The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 319% points. The greatest weakness of International Stem Cell CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 305% points.

The company's Economic Capital Ratio, given in the ranking table, is -384%, being 106% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	2,855
Cost of Goods Sold	2,122
Intangible Assets	2,922
Liabilities, Current	4,800
Liabilities, Non-Current	0
Other Assets	766
Other Compr. Net Income	0
Other Expenses	2,405
Other Liabilities	0
Other Net Income	-1,127
Property and Equipment	321
Research and Development	2,658
Revenues	7,456
Selling, General and Administrative Expense	5,213

Output Variable	Value in 1000 USD
Assets	6,864
Liabilities	4,800
Expenses	12,398
Stockholders Equity	2,064
Net Income	-6,069
Comprehensive Net Income	-6,069
Economic Capital Ratio	-384%



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai